ImmunityBio to Participate in UK Investor Conferences During London Life Sciences Week 2026
Business Wire•10/11/2026•21:31 ET
1
Key Highlights
- ➤ImmunityBio leadership will present at UBS and Jefferies conferences in London.
- ➤Presentations are scheduled for November 16 during London Life Sciences Week 2026.
- ➤Company will discuss QUILT-2.005 findings and earlier bladder-cancer treatment potential.
- ➤ANKTIVA expansion into BCG-naïve NMIBC remains investigational and FDA-unapproved.
Expert Statements
Richard Adcock, President and CEO of ImmunityBio
“The results from our QUILT-2.005 study bring us closer to our goal of treating bladder cancer earlier in the course of the disease. In London, we look forward to discussing what these findings could mean for patients who have not yet received BCG, our work to expand access to ANKTIVA globally, and where we see the greatest opportunity for our immunotherapy platform.”
ImmunityBio to Participate in UK Investor Conferences During London Life Sciences Week 2026
Senior leadership will discuss ImmunityBio’s clinical and commercial priorities at Jefferies Global Healthcare Conference and UBS Global Biopharma Conference in London
Get started
Create a free account to read the full story.